Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

The aim was to perform a broad phase II and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active against multidrug-resistant tumour cells in vitro when given by i.v. bolus at 1.5 mg m(-2) every 4 weeks, in metastatic or unresectable solid tumour patients with known intrinsic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, M., Droz, J. P., Hanauske, A. R., Verweij, J., van Oosterom, A. T., Groen, H. J., Pacciarini, M. A., Domenigoni, L., van Weissenbruch, F., Pianezzola, E., de Vries, E. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151269/
https://www.ncbi.nlm.nih.gov/pubmed/9459159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151269/
https://www.ncbi.nlm.nih.gov/pubmed/9459159

Ejemplares similares